HK1086284A1 - Kid3 and anti-kid3 antibodies kid3 kid3 - Google Patents
Kid3 and anti-kid3 antibodies kid3 kid3Info
- Publication number
- HK1086284A1 HK1086284A1 HK06108395.8A HK06108395A HK1086284A1 HK 1086284 A1 HK1086284 A1 HK 1086284A1 HK 06108395 A HK06108395 A HK 06108395A HK 1086284 A1 HK1086284 A1 HK 1086284A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- kid3
- antibodies
- kid3 antibodies
- kid3 kid3
- antibodies kid3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50444103P | 2003-09-18 | 2003-09-18 | |
PCT/US2004/030676 WO2005028498A2 (fr) | 2003-09-18 | 2004-09-17 | Kid3 et anticorps de liaison a kid3 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1086284A1 true HK1086284A1 (en) | 2006-09-15 |
Family
ID=34375495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06108395.8A HK1086284A1 (en) | 2003-09-18 | 2006-07-28 | Kid3 and anti-kid3 antibodies kid3 kid3 |
Country Status (14)
Country | Link |
---|---|
US (2) | US7790855B2 (fr) |
EP (1) | EP1664082B1 (fr) |
JP (1) | JP4621674B2 (fr) |
KR (2) | KR20060079236A (fr) |
CN (1) | CN101048425B (fr) |
AU (1) | AU2004274487B2 (fr) |
BR (1) | BRPI0414513A (fr) |
CA (1) | CA2539322C (fr) |
HK (1) | HK1086284A1 (fr) |
IL (1) | IL174304A (fr) |
MX (1) | MXPA06003014A (fr) |
NZ (1) | NZ545968A (fr) |
SG (1) | SG146644A1 (fr) |
WO (1) | WO2005028498A2 (fr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI407971B (zh) | 2007-03-30 | 2013-09-11 | Nitto Denko Corp | Cancer cells and tumor-related fibroblasts |
WO2009151717A2 (fr) | 2008-04-02 | 2009-12-17 | Macrogenics, Inc. | Anticorps spécifiques du complexe bcr et procédés pour les utiliser |
US20100291108A1 (en) * | 2007-10-16 | 2010-11-18 | Arie Abo | Antibodies to irem-1 |
CN106432503B (zh) | 2008-12-19 | 2020-03-06 | 宏观基因有限公司 | 共价双抗体及其用途 |
KR20120051733A (ko) * | 2009-08-04 | 2012-05-22 | 에프. 호프만-라 로슈 아게 | 베타 세포 마커 항체 |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
CA2791658C (fr) | 2010-03-04 | 2019-10-01 | Macrogenics, Inc. | Anticorps reagissant avec b7-h3, fragments immunologiquement actifs associes et utilisations associees |
JP5964300B2 (ja) | 2010-08-02 | 2016-08-03 | マクロジェニクス,インコーポレーテッド | 共有結合型ダイアボディおよびその使用 |
JP6145088B2 (ja) | 2011-05-21 | 2017-06-07 | マクロジェニクス,インコーポレーテッド | 脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用 |
CN103619355A (zh) | 2011-06-21 | 2014-03-05 | 日东电工株式会社 | 细胞凋亡诱导剂 |
JP6340162B2 (ja) | 2012-12-20 | 2018-06-06 | 日東電工株式会社 | アポトーシス誘導剤 |
JP6076076B2 (ja) | 2012-12-21 | 2017-02-08 | 日東電工株式会社 | 組織再生促進剤 |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
EP3148580B1 (fr) | 2014-05-29 | 2021-01-20 | MacroGenics, Inc. | Molécules de liaison tri-spécifiques se liant spécifiquement à de multiples antigènes tumoraux, et méthodes d'utilisation de celles-ci |
EP3159009B1 (fr) | 2014-06-17 | 2021-10-27 | Nitto Denko Corporation | Inhibiteurs de gst-pi et rb1cc1 pour le traitement du cancer |
JP6329501B2 (ja) * | 2015-03-11 | 2018-05-23 | アース環境サービス株式会社 | 昆虫の混入時期判定方法 |
PT3328419T (pt) | 2015-07-30 | 2021-11-26 | Macrogenics Inc | Moléculas de ligação pd-1 e métodos de utilização |
SG11201804839WA (en) | 2015-12-14 | 2018-07-30 | Macrogenics Inc | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
SG11201808979UA (en) | 2016-04-15 | 2018-11-29 | Macrogenics Inc | Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
AU2018224094A1 (en) | 2017-02-24 | 2019-09-19 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
AU2018385409A1 (en) | 2017-12-12 | 2020-07-02 | Macrogenics Inc. | Bispecific CD 16-binding molecules and their use in the treatment of disease |
JP7337079B2 (ja) | 2018-02-15 | 2023-09-01 | マクロジェニクス,インコーポレーテッド | 変異型cd3結合ドメイン、及び疾患の治療のための併用療法におけるその使用 |
GB201820547D0 (en) * | 2018-12-17 | 2019-01-30 | Oxford Univ Innovation | Modified antibodies |
US20220389117A1 (en) * | 2019-10-17 | 2022-12-08 | National Health Research Institutes | Use of succinate as biomarker in diagnosis and treatment of cancers |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3862925A (en) | 1973-07-05 | 1975-01-28 | American Home Prod | Preparation of somatotropin release inhibiting factor and intermediates therefor |
US3842067A (en) | 1973-07-27 | 1974-10-15 | American Home Prod | Synthesis of(des-asn5)-srif and intermediates |
JPS5726506B2 (fr) | 1974-03-08 | 1982-06-04 | ||
US4105603A (en) | 1977-03-28 | 1978-08-08 | The Salk Institute For Biological Studies | Peptides which effect release of hormones |
USRE30548E (en) | 1979-08-31 | 1981-03-17 | The Salk Institute For Biological Studies | Peptides which effect release of hormones |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5625037A (en) * | 1988-03-08 | 1997-04-29 | Reutter; Werner | Antibodies, method of preparing same, oligosaccharides and clones for providing said antibodies, and the use of said antibodies for tumor diagnosis and therapy |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5552391A (en) | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
WO1994004679A1 (fr) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Procede pour fabriquer des anticorps humanises |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
US5532159A (en) | 1994-04-01 | 1996-07-02 | The Ohio State University | Monoclonal antibody to canine placental oncofetal protein for detecting cancer |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
US6143540A (en) * | 1999-01-26 | 2000-11-07 | Millennium Pharmaceuticals, Inc. | Molecules of the HKID-1-related protein family and uses thereof |
BR122014028365B8 (pt) * | 1999-06-25 | 2021-07-06 | Genentech Inc | artigo industrializado compreendendo um primeiro recipiente que compreende uma composição de humab4d5-8 nele contida e um segundo recipiente que compreende uma composição rhumab 2c4 nele contida |
US6406840B1 (en) | 1999-12-17 | 2002-06-18 | Biomosaic Systems, Inc. | Cell arrays and the uses thereof |
US20020119919A1 (en) | 2000-01-31 | 2002-08-29 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
AU2001250898A1 (en) * | 2000-03-17 | 2001-10-03 | The Salk Institute For Biological Studies | Compositions associated with complex formation |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
-
2004
- 2004-09-17 BR BRPI0414513-5A patent/BRPI0414513A/pt not_active Application Discontinuation
- 2004-09-17 EP EP04784523.5A patent/EP1664082B1/fr not_active Not-in-force
- 2004-09-17 JP JP2006527095A patent/JP4621674B2/ja not_active Expired - Fee Related
- 2004-09-17 NZ NZ545968A patent/NZ545968A/en not_active IP Right Cessation
- 2004-09-17 WO PCT/US2004/030676 patent/WO2005028498A2/fr active Application Filing
- 2004-09-17 KR KR1020067005406A patent/KR20060079236A/ko not_active Application Discontinuation
- 2004-09-17 US US10/943,640 patent/US7790855B2/en not_active Expired - Fee Related
- 2004-09-17 KR KR1020087027086A patent/KR100935855B1/ko not_active IP Right Cessation
- 2004-09-17 AU AU2004274487A patent/AU2004274487B2/en not_active Ceased
- 2004-09-17 MX MXPA06003014A patent/MXPA06003014A/es active IP Right Grant
- 2004-09-17 CA CA2539322A patent/CA2539322C/fr not_active Expired - Fee Related
- 2004-09-17 CN CN2004800338722A patent/CN101048425B/zh not_active Expired - Fee Related
- 2004-09-17 SG SG200806893-4A patent/SG146644A1/en unknown
-
2006
- 2006-03-14 IL IL174304A patent/IL174304A/en not_active IP Right Cessation
- 2006-07-28 HK HK06108395.8A patent/HK1086284A1/xx not_active IP Right Cessation
-
2010
- 2010-07-07 US US12/831,858 patent/US8440197B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2539322A1 (fr) | 2005-03-31 |
SG146644A1 (en) | 2008-10-30 |
MXPA06003014A (es) | 2006-06-23 |
AU2004274487B2 (en) | 2011-09-01 |
NZ545968A (en) | 2010-01-29 |
US8440197B2 (en) | 2013-05-14 |
CN101048425B (zh) | 2012-12-26 |
KR20080106374A (ko) | 2008-12-04 |
CN101048425A (zh) | 2007-10-03 |
WO2005028498A3 (fr) | 2007-06-28 |
WO2005028498A2 (fr) | 2005-03-31 |
US20100322851A1 (en) | 2010-12-23 |
EP1664082B1 (fr) | 2014-03-05 |
BRPI0414513A (pt) | 2007-01-02 |
EP1664082A4 (fr) | 2008-09-24 |
EP1664082A2 (fr) | 2006-06-07 |
US7790855B2 (en) | 2010-09-07 |
US20050152907A1 (en) | 2005-07-14 |
CA2539322C (fr) | 2016-07-12 |
KR20060079236A (ko) | 2006-07-05 |
IL174304A0 (en) | 2008-02-09 |
JP2007529197A (ja) | 2007-10-25 |
AU2004274487A1 (en) | 2005-03-31 |
JP4621674B2 (ja) | 2011-01-26 |
IL174304A (en) | 2014-11-30 |
KR100935855B1 (ko) | 2010-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1086284A1 (en) | Kid3 and anti-kid3 antibodies kid3 kid3 | |
IL225633A0 (en) | Antibodies against alpha v beta 6 and uses thereof | |
IL182554A0 (en) | Anti-addl antibodies and uses thereof | |
EP1551447A4 (fr) | Anticorps anti-addl et leurs utilisations | |
ZA200603882B (en) | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides | |
IL175491A0 (en) | Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides | |
IL172871A0 (en) | Rg1 antibodies and uses thereof | |
IL178277A0 (en) | Irta-5 antibodies and their uses | |
HK1088837A1 (en) | Clk-peptide and slk-peptide | |
ZA200703406B (en) | Anti-ADDL antibodies and uses thereof | |
EP1699485A4 (fr) | Anticorps anti-hydroxylase et utilisations | |
IL172510A0 (en) | Antibodies and uses thereof | |
EP1711527A4 (fr) | Anticorps specifiques de hla-dr, compositions et methodes associees | |
EP1589033A4 (fr) | Anticorps et utilisation de ce dernier | |
GB0202871D0 (en) | Assays,methods and means | |
IL166063A0 (en) | Antibodies and uses thereof | |
GB0314741D0 (en) | Reagents and methods | |
GB0424552D0 (en) | Methods and means | |
GB0403847D0 (en) | Methods and means | |
GB0314743D0 (en) | Reagents and methods | |
EP1627888A4 (fr) | Anticorps et son utilisation | |
ZA200702281B (en) | IRTA-4 antibodies and their uses | |
GB0421911D0 (en) | Methods and means | |
GB0227080D0 (en) | Antibodies and uses thereof | |
GB0202565D0 (en) | Assay methods and means |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20180917 |